Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIODEGRADE: Orsiro vs Biomatrix Stents in CAD
NCT02299011Phase 4Completed
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jul 2014
- Primary completion
- Jun 2019
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronary artery disease (CAD) and Myocardial ischemia (MI) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Target lesion failure at 18 months. Started Jul 2014; status: completed.
02
Conditions
coronary artery disease (CAD)Myocardial ischemia (MI)
Beyond the preview
Go deeper on NCT02299011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02299011.